This article provides the highlights of this clinical trial conducted on 24000+ arthritic patients to assess the cardiovascular, gastrointenstinal, renal, and other outcomes with celecoxib, as compared to ibuprofen or naproxen. The trial included patients who required non-steroidal antiinfammatory drugs (NSAIDs) for osteoarthritis or rheumatoid arthritis, who were at increased risk of cardiovascular disease. Over the years, non-steroidal antiinflammatory drugs (NSAIDs) have become the most widely prescribed class of drugs in the world.
NSAIDs inhibit cyclooxygenase (COX), which reduces pain and inflammation through the inhibition of prostaglandins. However, the COX inhibitor is also presented in the gastric mucosa, where it stimulates gastroprotective prostaglandins. The two isoforms are identified as COX-1 and COX-2, and the recognition of antiinflammatory and analgesic effects are…
